Developing AI-Enabled Optical Detection Systems for Tumor Margin Assessment and Tissue Characterization

Unseen cancer revealed

Become A Research Partner

The New Generation of Assessment

When it comes to cancer treatment, even the smallest amount of leftover tissue can lead to recurrence. Reveal combines an AI engine that provides real-time tissue diagnostics, sophisticated optical techniques, and an intuitive probe that can be manipulated easily during surgery. We give world-class surgeons the ability to confidently identify previously undetected cancerous tissue in vivo, giving patients a greater chance at a healthier life.

What Is Reveal?

Our Technology

Surgeons are often faced with critical decisions in real-time. With little margin for error, greater tumor cell identification and precise excision are key – remove too little tissue and risk fatal recurrences or remove too much and cause profound neurological damage. Learn more about how Reveal’s technology is tackling this problem.

More Tech

The Sentry™

Our future flagship product for neurosurgery. Our intraoperative platform brings the diagnostic capability of Raman Spectroscopy and the power of AI to the hands of surgeons.

We aim to allow surgeons to make in vivo, real-time measurements of brain tissue and identify the presence of invasive cancer cells, at the sub-millimeter scale. Investigational studies have shown Raman-based classifiers can reveal invasive cancer past the boundary of MRI with high accuracy, sensitivity, and specificity. We are developing our product to harness this precision for the moments it’s needed most. Learn more on our Technology Page.

*Currently for investigational use only

Partners

Our research partners are helping us to lead the charge in tumour identification innovation.

Our investors are helping us to lead the charge in tumour identification innovation.

ISO 13485 certification

Reveal Surgical is very proud to announce we are now ISO 13485 certified!

ISO 13485 is the internally recognized gold standard for quality in the medical device industry. Certification to this standard demonstrates that we take quality very seriously and that we have a system in place to ensure it. Not only do we comply with best practices, and with regulatory requirements, but we are now in the best possible position to ensure continuous improvement.

View certification

Become A Research Partner

With your help, we can continue to discover new methods of tissue characterization, together changing the landscape of medicine.

Let's Talk

In The Press

February 04, 2022

AI ‘Fingerprinting’ Fights Back Against Hard-to-Detect Cancers

November 25, 2021

Detecting the previously undetectable

November 19, 2021

Made in Quebec: Illuminating hidden brain cancer cells

November 09, 2021

ODS Medical Inc has rebranded as Reveal Surgical

September 01, 2020

ODS Medical, Inc. closes a new financing round to further support product development diversification of applications

August 01, 2019

ODS Medical Inc. announces Sentry™ System prototype for real-time Raman spectroscopy receives Health Canada testing authorization

May 27, 2019

Innovation, Science and Economic Development Canada announces $49 Million investment in DHDP

October 25, 2018

ODS Medical joins forces with two American Giants

July 01, 2018

ODS Medical is a 2018 Medtech Innovator Showcase Company

January 12, 2018

Frédéric Leblond in the running for discovery of the year

Tissue Characterization Systems For Tumor Assessment | Reveal

Web Name: Tissue Characterization Systems For Tumor Assessment | Reveal

WebSite: http://www.odsmed.com

ID:293329

Keywords:

Description:

Developing AI-Enabled Optical Detection Systems for Tumor Margin Assessment and Tissue Characterization

Unseen cancer revealed

The New Generation of Assessment

What Is Reveal?

Our Technology

The Sentry™

Partners

ISO 13485 certification

Become A Research Partner

In The Press

<<< Thank you for your visit >>>

WHY YOU SHOULD Be listed